Nautilus Biotechnology (NAUT) Non-Current Assets (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Non-Current Assets of $76.0 million for Q2 2026, down 3.8% sequentially from $78.9 million in Q1 2026, and up 21.59% YoY from $62.5 million in Q2 2025.
Nautilus Biotechnology (NAUT) Non-Current Assets (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Non-Current Assets for 7 years, with the latest figure at $76.0 million in Q2 2026.
- Quarterly Non-Current Assets rose 21.59% year-over-year to $76.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $306.6 million (down 18.0% YoY) and the FY2025 annual result came in at $85.1 million, down 22.53% from the prior year.
- Non-Current Assets declined to $76.0 million in Q2 2026 per NAUT's latest filing, from $78.9 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $175.4 million in Q1 2023 and troughed at $57.6 million in Q1 2022.
- A 5-year average of $104.0 million and a median of $99.9 million in 2022 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 266.07% in 2022, down 61.48% in 2022.
- Over 5 years, Non-Current Assets stood at $162.8 million in 2022, then decreased by 20.95% to $128.7 million in 2023, then fell by 14.61% to $109.9 million in 2024, then slipped by 22.53% to $85.1 million in 2025, then fell by 10.8% to $76.0 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $76.0 million, $78.9 million, and $85.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 18.06 Bn |
| 10 | Nautilus Biotechnology | 116.56 Mn | 116.56 Mn | 175,000.00 | 75.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75.95 Mn |
| Mar 31, 2026 | 78.95 Mn |
| Dec 31, 2025 | 85.15 Mn |
| Sep 30, 2025 | 66.59 Mn |
| Jun 30, 2025 | 62.46 Mn |
| Mar 31, 2025 | 86.09 Mn |
| Dec 31, 2024 | 109.92 Mn |
| Sep 30, 2024 | 115.50 Mn |
| Jun 30, 2024 | 101.81 Mn |
| Mar 31, 2024 | 103.56 Mn |
| Dec 31, 2023 | 128.73 Mn |
| Sep 30, 2023 | 131.55 Mn |
| Jun 30, 2023 | 164.06 Mn |
| Mar 31, 2023 | 175.40 Mn |
| Dec 31, 2022 | 162.84 Mn |
| Sep 30, 2022 | 98.08 Mn |
| Jun 30, 2022 | 68.26 Mn |
| Mar 31, 2022 | 57.61 Mn |
| Dec 31, 2021 | 49.23 Mn |
| Sep 30, 2021 | 33.13 Mn |